Manufacturer record
INDU Drugs Pvt Ltd.5-5- 35/278: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
1 batch manufactured by INDU Drugs Pvt Ltd.5-5- 35/278 (Telangana) was declared Not of Standard Quality in April 2025. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: PXT123F02, Proxtl 100 DT (exp May 2025). CDTL Mumbai (CDSCO lab) found it not of standard quality: The sample does not comply with IP requirements for Dissolution test. Listed in the April 2025 alert.
Records by type
1 record linked to INDU Drugs Pvt Ltd.5-5- 35/278 in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Proxtl 100 DT | Batch PXT123F02Mfg Mar 2023 · Exp May 2025 | The sample does not comply with IP requirements for Dissolution test.Dissolution | CDTL MumbaiCDSCO lab | Apr 2025 |
Batches reported as suspected spurious under this label
CDSCO's spurious-drug alerts list batches that purport to be made by a company but are suspected counterfeits. The labelled manufacturer's reply is shown where CDSCO published it.
| Product | Batch | Reported by | Firm's reply | Alert |
|---|---|---|---|---|
| Deflazacort Tablets 6 mg Defcort 6 | 13240334A | RDTL, Chandigarh | The actual manufacturer (as per label claim) has informed that the impugned batch of the product has not been manufactured by them and that it is a spurious drug. | Dec 2025 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.